Home ›
Entities
› academia
› Safety and Activity of Flotetuzumab in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results from the COG PEPN1812 Phase 1 Trial
Safety and Activity of Flotetuzumab in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results from the COG PEPN1812 Phase 1 Trial
Research article (Blood, 2022) · cited 14× · AI/ML
Safety and Activity of Flotetuzumab in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results from the COG PEPN1812 Phase 1 Trial
Summary
Safety and Activity of Flotetuzumab in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results from the COG PEPN1812 Phase 1 Trial is a scholarly article[1].
Key Facts
Safety and Activity of Flotetuzumab in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results from the COG PEPN1812 Phase 1 Trial's instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). Safety and Activity of Flotetuzumab in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results from the COG PEPN1812 Phase 1 Trial. Retrieved May 24, 2026, from https://4ort.xyz/entity/safety-and-activity-of-flotetuzumab-in-pediatric-and-young-adult-patients-with-relapsed-refractory-acute-myeloid-leukemi
MLA“Safety and Activity of Flotetuzumab in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results from the COG PEPN1812 Phase 1 Trial.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/safety-and-activity-of-flotetuzumab-in-pediatric-and-young-adult-patients-with-relapsed-refractory-acute-myeloid-leukemi.
BibTeX@misc{4ortxyz_safety-and-activity-of-flotetuzumab-in-pediatric-and-young-adult-patients-with-relapsed-refractory-acute-myeloid-leukemi_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Safety and Activity of Flotetuzumab in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results from the COG PEPN1812 Phase 1 Trial}}, year = {2026}, url = {https://4ort.xyz/entity/safety-and-activity-of-flotetuzumab-in-pediatric-and-young-adult-patients-with-relapsed-refractory-acute-myeloid-leukemi}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Safety and Activity of Flotetuzumab in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results from the COG PEPN1812 Phase 1 Trial — https://4ort.xyz/entity/safety-and-activity-of-flotetuzumab-in-pediatric-and-young-adult-patients-with-relapsed-refractory-acute-myeloid-leukemi (retrieved 2026-05-24)
